Novo Holdings A S Has $16.22 Million Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Novo Holdings A S increased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 7.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,500,000 shares of the company's stock after acquiring an additional 100,000 shares during the period. 4D Molecular Therapeutics makes up 0.8% of Novo Holdings A S's portfolio, making the stock its 27th biggest position. Novo Holdings A S owned approximately 2.90% of 4D Molecular Therapeutics worth $16,215,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Redmile Group LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth approximately $40,189,000. Assenagon Asset Management S.A. lifted its position in 4D Molecular Therapeutics by 238.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company's stock worth $16,684,000 after purchasing an additional 1,087,147 shares during the period. RA Capital Management L.P. boosted its stake in 4D Molecular Therapeutics by 21.3% during the 1st quarter. RA Capital Management L.P. now owns 5,051,511 shares of the company's stock valued at $160,941,000 after purchasing an additional 888,300 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of 4D Molecular Therapeutics by 1,076.1% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 641,000 shares of the company's stock valued at $20,422,000 after purchasing an additional 586,500 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 25.3% in the 1st quarter. Vanguard Group Inc. now owns 2,339,943 shares of the company's stock worth $74,551,000 after buying an additional 473,094 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

FDMT has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, September 23rd. Royal Bank of Canada reissued an "outperform" rating and set a $40.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 22nd. BMO Capital Markets decreased their price target on shares of 4D Molecular Therapeutics from $63.00 to $40.00 and set an "outperform" rating on the stock in a research report on Thursday, July 18th. Finally, Leerink Partners reiterated an "outperform" rating and set a $36.00 price objective (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $47.14.

4D Molecular Therapeutics Trading Down 0.7 %

NASDAQ:FDMT traded down $0.06 during trading hours on Friday, hitting $8.15. 497,270 shares of the stock traded hands, compared to its average volume of 991,322. The firm has a 50 day moving average price of $12.40 and a 200 day moving average price of $18.83. The firm has a market cap of $423.56 million, a price-to-earnings ratio of -3.54 and a beta of 2.77. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $7.90 and a fifty-two week high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.09. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $1.90 million. Research analysts predict that 4D Molecular Therapeutics, Inc. will post -2.74 EPS for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.